



Overview of GLP test facilities inspected

Country: **AUSTRIA**

Name of monitoring authority: **Federal Office for Safety in Health Care (BASG)**

Date of publication: 27.03.2026

TEST FACILITY	DATE OF INSPECTION	STATUS	NATURE OF INSPECTION	AREA OF EXPERTISE	REMARKS
[Name (bold type) and full address of test facility]	[mm.yyyy]	[ic/nic/pen/rfp]	[full/re-i/fac/sa]	[1-8, 9: specify]	(for example: refer to nic notification)
Bionorica research GmbH Mitterweg 24, 6020 Innsbruck	02.2026	pen	full	8	<i>pen: awaiting finalisation of inspection procedure</i>
GLP Prüfeinrichtung Takeda Manufacturing Austria AG (Takeda Manufacturing Austria AG, a subsidiary of Baxalta Innovations GmbH) Industriestraße 67, 1221 Vienna Test sites: <ul style="list-style-type: none">• Benatzkygasse 2-6, 1221 Vienna• Industriestraße 67, 1221 Vienna	04.2023	ic	full	9	9: Safety Pharmacology, Virus and Prion Biosafety Studies New name since 01/2022 Formerly: Baxalta Innovations GmbH
Institute Krems Bioanalytics TFZ, Magnesitstr. 1, 3500 Krems IMC Fachhochschule Krems GmbH/ IMC University of Applied Sciences Krems Piaristengasse 1, 3500 Krems	05.2024	ic	full	8	
JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH – Institute for Biomedicine and Health Sciences Neue Stiftingtalstraße 2, 8010 Graz	10.2023	ic	full	1, 8	



Overview of GLP test facilities inspected

TEST FACILITY	DATE OF INSPECTION	STATUS	NATURE OF INSPECTION	AREA OF EXPERTISE	REMARKS
pharm-analyt Labor GmbH Ferdinand-Pichler-Gasse 2, 2500 Baden Test sites: <ul style="list-style-type: none">Ferdinand-Pichler-Gasse 2, 2500 BadenArchive: Leesdorfer Hauptstraße 8, 2500 Baden (since 12.2012)	10.2024	ic	full	8, 9	9: Chromatographic testing of formulations (serum, blood, urine and tissue) for toxicological studies and pharmacokinetic studies
SALK - Forschungsinstitut für Neurointerventionen (FINI) Ignaz-Harrer-Straße 79, 5020 Salzburg Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH (SALK) Müllner Hauptstraße 48, 5020 Salzburg	05.2024	ic	full	9	9: Functionality Testing of Medical Devices
VelaLabs GmbH Brunner Straße 69, Objekt 3, 1230 Wien	07.2024	ic	full	9	9: Bioanalytical Testing and Quality Control
VirusSure Forschung und Entwicklung GmbH Donau-City-Straße 1, Tech Gate Science and Technology Park, Bauteil Gate, 1220 Vienna Test sites: <ul style="list-style-type: none">Tech Gate Vienna, Modul Gate levels -2 und -3, Donau-City-Straße 1, 1220 Viennain vivo Test Facility at University of Natural Resources and Life Sciences, Muthgasse 11/2, 1190 Vienna	09.2024	ic	full	8, 9	8: PCR tests 9: Virus and Prion Biosafety Testing, Sanger Sequencing



Overview of GLP test facilities inspected

TEST FACILITY	DATE OF INSPECTION	STATUS	NATURE OF INSPECTION	AREA OF EXPERTISE	REMARKS
Zentrum für Biomedizinische Forschung und Translationale Chirurgie Medizinische Universität Wien, AKH, Leitstelle 1Q, Währinger Gürtel 18-20, 1090 Wien	02.2026	pen	full	2, 9	9: Pharmacological studies, Testing of medical devices (biological evaluation of medical devices) <i>pen: awaiting finalisation of inspection procedure</i>

Status

GLP compliance status. Please use one of the following codes:

- ic (in compliance);
- nic (not in compliance);
- pen (pending, explanation in *Remarks* field);
- rfp (removed from programme).

Nature of inspection

Please use one of the following codes:

- fac (facility inspection);
- sa (study audit);
- full (fac+sa);
- re-i (re-inspection as follow-up to full inspection).

In case one or more studies have been found to be 'nic' during a full inspection that did not result in a 'nic' test facility status, each should be separately listed as 'sa' and 'nic';



Overview of GLP test facilities inspected

Area of expertise

The following codes should be used, if applicable. The OECD Test Guidelines listed in brackets after each category is for guidance only as other appropriate methodologies can be used for studies. There may be also some studies that obviously fall into a category even though an OECD Test Guideline is not available.

- 1 Physical-chemical testing (Section 1 - Physical Chemical Properties);
- 2 Toxicity testing (Section 4 - Health Effects No 401 – 453);
- 3 Mutagenicity testing (Section 4 - Health Effects No 471 – 486);
- 4 Environmental toxicity studies on aquatic and terrestrial organisms (Section 2 - Effects on Biotic Systems);
- 5 Studies on behaviour in water, soil and air; bioaccumulation (Section 3 - Degradation and Accumulation);
- 6 Residue studies (Section 5 - Pesticides Residue Chemistry);
- 7 Studies on effects on mesocosms and natural ecosystems (Section 2 - Effects on Biotic Systems);
- 8 Analytical and clinical chemistry testing;
- 9 Other studies. If this code is used, please specify exactly what type of study is covered in either the "Area of Expertise" or "Remarks" field.

On Behalf of the Federal Office for Safety in Health Care

DI Dr. Ronald Bauer
Head of Institute Surveillance

electronic signature on final page

Bauer Ronald
am 27.3.2026